Stereotaxis (STXS) Reports Q1 Loss of $0.11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Stereotaxis Reports 2016 First Quarter Financial Results
May 9, 2016 4:06 PM EDTVentricular tachycardia procedures increased 27% year over year, representing the third consecutive quarter of 20%+ volume growthFourth Niobe® system shipped to JapanPatient enrollment completed for Niobe® post-market surveillance in JapanClinical literature expands to more than 260 peer-reviewed articlesOperating expenses decreased 4% from the year-ago quarterConference call today at 4:30 p.m. Eastern Time
ST. LOUIS, May 09, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ: STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2016.Â
We made... More
